UNSPSC 51433202: Darusentan

This classification denotes an endothelin receptor antagonist and antihypertensive agent with the molecular formula C22H22N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 33JD57L6RW, chemically known as benzenepropanoic acid, alpha-((4,6-dimethoxy-2-pyrimidinyl)oxy)-beta-methoxy-beta-phenyl-, (s)- but generally known as darusentan, which bears US NIH Compound Identifier 177236. European Medicines Agency schedules Darusentan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32910.

UNSPSC 51433202 Darusentan, a Commodity code, encompasses emergency and acute-care medications procured by state and local health agencies, fire departments, and pharmacy benefit programs. State and local governments are buying specific branded and generic pharmaceutical products for advanced life support protocols, emergency medical services, and pharmacy benefit management programs. Recent solicitations show municipalities and state health agencies acquiring individual medication units with tight expiration-date requirements, while state cooperative purchasing alliances are establishing master agreements for multi-source generic pharmaceuticals distributed through authorized wholesalers. Issuing bodies include city purchasing departments (Tampa Fire Rescue procurement through the City of Tampa), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering contracts for participating state and local government facilities).

Geographic activity centers on Texas, Florida, and Minnesota, with cooperative agreements extending to Oregon and other participating jurisdictions. Representative recent opportunities include the City of Tampa's sealed-bid solicitation (26P00188) for Advanced Life Support Medications due April 8, 2026, requiring 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials with a one-year contract term and estimated value of $40,000.00; the Texas HHS Commission's Request for Information (HHS0017013) posted April 3, 2026, exploring direct-to-manufacturer prescription fulfillment capabilities outside traditional PBM and GPO channels; and the Minnesota Multistate Cooperative Purchasing Alliance's Request for Proposal (S1070000015802) due March 26, 2026, establishing multi-award contracts for generic pharmaceuticals and OTC products effective July 1, 2026, distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co. Vendors must maintain FDA compliance, cGMP certification, and expiration dates meeting minimum shelf-life standards; Tampa's solicitation includes a 5 percent bid discount for Small Local Business Enterprise participation.